EICHOR
● Recruiting
Metabolic and Metagenomic Effects of Intestinal Microbiome Repopulation in Unexplained Atherosclerosis
Condition: Atherosclerosis · Intestinal Microbiome · Sponsor: Western University, Canada
About this study
Patients with unexplained atherosclerosis (severe atherosclerosis not explained by traditional risk factors) will receive fecal microbial transplants (FMT) from patients with a Protected phenotype (patients who have high levels of risk factors but little or no carotid atherosclerosis). The objective is to determine what changes in the intestinal microbiome are associated with a decline in plasma levels of toxic metabolites of the itnestinal microbiome such as trimethylamine N-oxide (TMAO) and p-cresylsulfate. The intention is to develop an ecosystem therapeutic of cultured bacteria to treat atherosclerosis.
This description comes directly from the study's public registry record.
Talk to the study team
J. David Spence, M.D. · 1-519-931-5731 · dspence@robarts.ca
Leslie Paddock, R.N. · 1-519-931-5731 · leslie.paddock@lhsc.on.ca
Always discuss trial participation with your own doctor first.
Locations (1)
| Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute | London, Ontario, Canada | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04410003